# US 2017/0281748 A1 · Multi-CBV Vaccine for Preventing or Treating Type I Diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281748 A1
- Document ID: US20170281748A1
- Status: Published application
- Kind: A1
- Application number: 15/465,854
- Filed: 2017-03-22
- Published: 2017-10-05
- Earliest claimed: 2011-10-18
- Assignees: Vactech Oy
- Applicants: Vactech Oy
- Inventors: Hyöty Heikki; Mikael Knip; Olli Laitinen; Outi Tolonen; Minna Pulkki; Sami Oikarinen; Hanna-Riikka Honkanen; Valérie Lecouturier; Jeffrey Almond; Malin Flodström-Tullberg
- Web page: https://patentgrep.com/patent/US20170281748A1

## CPC

- A61K 39/125: Picornaviridae, e.g. calicivirus
- A61K 39/12: Viral antigens
- A61K 39/13: Poliovirus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- C07K 16/106: Picornaviridae (F), e.g. hepatitis A virus
- A61K 2039/505: {comprising antibodies}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- C12N 2770/32334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.

## Claims

### Claim 1

A method of inducing an immune response to coxsackie B virus (CBV) in an individual, the method consisting of administering to the subject an effective amount of a composition comprising:
a) CBV1 and CBV2 in inactivated form or in the form of a subunit or a virus-like particle (VLP); and
b) at least one CBV selected from the group consisting of CBV3, CBV4, CBV5, and CBV6 in inactivated form or in the form of a subunit or a VLP,
wherein said administering induces an immune response to CBV in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the CBVs are inactivated.

### Claim 3 (depends on 1)

The method of claim 1, wherein the CBVs are in the form of a subunit of the CBVs.

### Claim 4 (depends on 1)

The method of claim 1, wherein the CBVs are in the form of VLPs of the CBVs.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition comprises CBV1, CBV2, CBV3, CBV4, CBV5 and CBV6 in inactivated form or in the form of a subunit or a VLP.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition comprises a pharmaceutically acceptable excipient.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition comprises an adjuvant.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a pregnant woman.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject is a child.

### Claim 10 (depends on 9)

The method of claim 9, wherein the composition is administered to the child within one year after birth.

### Claim 11 (depends on 10)

The method of claim 10, wherein the composition is administered to the child within 2 years after birth.

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition is administered intramuscularly.

### Claim 13 (depends on 1)

The method of claim 1, wherein the composition is administered subcutaneously.
